Among 255,730 statin-naïve adults aged 40 to 84 started on statins for primary prevention between 2017 and 2020, the 67.7% with a recorded CVD risk score at initiation showed 7% higher adherence and 8% fewer discontinuations over a mean 4.6 years of follow-up. They also had a 15% lower rate of CVD events and all-cause death, a gap larger than adherence differences alone could explain.
The adherence finding fits what we know: patients who understand their personal risk are more likely to keep taking a preventive drug. The mortality gap is the surprising part, and it deserves skepticism. This is a retrospective observational cohort, and a documented risk score likely marks something else: more engaged patients, more thorough practices, better follow-up, blood pressure control, or healthier baseline profiles. Healthy-adherer and healthy-user bias are classic traps in statin research, and the authors themselves acknowledge the effect cannot be fully explained by adherence. Residual confounding is the most plausible explanation; a causal effect of the conversation itself would be extraordinary. For adults, the practical takeaway is modest but real: if a statin is proposed for primary prevention, ask for your estimated 10-year risk and discuss benefits and trade-offs before starting, because informed starters appear more likely to persist. This is confirmatory on adherence and hypothesis-generating on mortality. A randomized trial of structured risk communication would be needed to test whether the survival signal is real.